GlassScriptPhysician profile
Ric S Garrison
NPI 1295814408
$22,285.30
in general payments reported to CMS, 2019-2025
89 companies · $2,237 in 2025
The $2,237 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,477 · 2020: $2,053 · 2021: $4,261 · 2022: $3,436 · 2023: $3,883 · 2024: $2,938 · 2025: $2,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,722 · Debt Forgiveness: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,721.96 |
| Debt Forgiveness | $1,335.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,548.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,441.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Optos, INC. | $1,354.92 | 2021-2023 | Nfc-700 |
| Lilly USA, LLC | $1,344.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,282.51 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,259.48 | 2021 | |
| Merck Sharp & Dohme LLC | $1,082.71 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $951.95 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $879.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $583.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $569.56 | 2019-2024 | Trelegy Ellipta |
| Merz North America, INC. | $541.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $517.13 | 2021-2025 | Dupixent |
| Gilead Sciences, INC. | $493.67 | 2021-2025 | Epclusa |
| Corcept Therapeutics | $483.19 | 2022-2025 | Korlym |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ric Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.